Compare Cronos Group Inc (CRON) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Altria Group Inc — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while Altria Group Inc trades at $71.86 (market cap $119.25B). The key difference: Altria Group Inc is far larger — about 101.1× Cronos Group Inc's market cap, and Altria Group Inc pays a 6.22% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Altria Group Inc for 154 Days on average.
| CRON | MO | |
|---|---|---|
Market Cap | $1.18B | $119.25B |
Volume | 968,037 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $3.55 | $74.92 |
52-Week Low | $2.30 | $54.72 |
Typical Hold Time | 22 Days | 154 Days |
Enterprise Value | $387.62M | $141.46B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
Altria Group (MO) trades at $71.89, up 3.61% with a bullish technical signal from moving averages. The company maintains strong profitability with 39% net margins and generates robust operating cash flow of $9.29B, supporting its 6.6% dividend yield. Recent earnings show mixed results with one beat and two misses in the last four quarters. The stock trades below analyst consensus target of $69.71 despite negative shareholder equity of -$2.24B due to high debt levels.
MO offers income investors an attractive dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. Analyst consensus remains positive with 61.5% buy ratings, though concerns persist about the sustainability of dividend payments given the company's negative equity position and competitive pressures in smoke-free alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
